107
Views
17
CrossRef citations to date
0
Altmetric
Original Research

Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?

, , , , , & show all
Pages 2387-2396 | Published online: 09 Nov 2018

References

  • MerzMSalwenderHHaenelMSubcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialHaematologica2015100796496925840597
  • CornellRFKassimAAEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityBone Marrow Transplant201651447949126726946
  • StewartAKRajkumarSVDimopoulosMACarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
  • KubiczkovaLPourLSedlarikovaLHajekRSevcikovaSProteasome inhibitors – molecular basis and current perspectives in multiple myelomaJ Cell Mol Med201418694796124712303
  • MoreauPMassziTGrzaskoNOral Ixazomib, Lenalidomide, And Dexamethasone For Multiple MyelomaN Engl J Med2016374171621163427119237
  • HariPRomanusDPalumboAProlonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United StatesClin Lymphoma Myeloma Leuk201818215216029395837
  • MühlbacherACNüblingMAnalysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myelomaEur J Health Econ201112319320320107856
  • MühlbacherACLinckeHJNüblingMEvaluating patients’ preferences for multiple myeloma therapy, a Discrete-Choice-ExperimentPsychosoc Med20085Doc10
  • BarbeeMSHarveyRDLonialSSubcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferencesAnn Pharmacother20134791136114224259728
  • LassalleAThomaréPFronteauCHome administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center studyAnn Oncol201627231431826578729
  • LeleuXMateosM-VDelforgeMAssessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice StudyBlood2015126232086
  • Reed JohnsonFLancsarEMarshallDConstructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceValue Health201316131323337210
  • Hüttl MaackVHelmRSteinerMA customer-based approach for selecting attributes and levels for preference measurement and new product developmentInt J Product Devel2016214233
  • JanssenEMMarshallDAHauberABBridgesJFPImproving the quality of discrete-choice experiments in health: how can we assess validity and reliability?Expert Rev Pharmacoecon Outcomes Res201717653154229058478